Page 13 - Briefing Document News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article NEW YORK, May 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On May 4, 2021, the U.S. Food and Drug Administration ("FDA") released a "Briefing Document" concerning Ch...

Share this article Share this article RADNOR, Pa., May 6, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of those who purchased or acquired ChemoCentryx common stock between November 26, 2019 and May 3, 2021, inclusive (the "Class Period"). Deadline Reminder: Investors who purchased or acquired ChemoCentryx common stock during the Class Period may, no later than July 6, 2021, seek to be appointed as a lead plaintiff representati...

Message : Required fields NEW YORK, May 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether ChemoCentryx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  On May 4, 2021, the U.S. Food and Drug Administration ("FDA") released a "Briefing Document" concerning ChemoCentryx...

Share this article Share this article NEW YORK, May 6, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of ChemoCentryx, Inc. ("ChemoCentryx" or the "Company") (NASDAQ: CCXI) from November 26, 2019 through May 3, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934. If you  purchased ChemoCentryx secur...

Moderna on Friday evening became the second developer of a COVID-19 vaccine to be granted an emergency use authorization (EUA) by the FDA, allowing patients to be dosed with the company’s messenger RNA (mRNA)-based mRNA-1273—just a week after the agency granted the first. The company said the first doses of mRNA-1273 will be injected into patients next week. Like Pfizer and BioNTech’s BNT162b2, which received an EUA on December 11, mRNA-1273 is a two-dose vaccine. But Moderna’s vaccine is indicated for the prevention of COVID-19 in individuals 18 years of age and older, rather than 1...